MedTrace Logo

Corifollitropin Alfa Followed by hpHMG in a Long GnRH Agonist Protocol for the Treatment of Poor Ovarian Responders

NCT01732094 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2013-05-09

No results posted yet for this study

Summary

The purpose of the present study is to examine the level of ovarian response and the pregnancy rates among poor ovarian responders treated with a novel treatment protocol with 150μg corifollitropin alfa followed by 300IU hMG in a long GnRH agonist protocol.

Conditions

Interventions

DRUG

Triptorelin

Triptorelin 0.1 mg/1 ml solution daily from day 21 of the cycle onwards

DRUG

Corifollitropin alfa 150μg

Corifollitropin alfa 150μg (single dose) 2 or 3 weeks after initiation of triptorelin

DRUG

hpHMG

hpHMG 300IU daily from day 7 following Corifollitropin alfa onwards

Sponsors & Collaborators

  • Universitair Ziekenhuis Brussel

    lead OTHER

Principal Investigators

  • Nikolaos P. Polyzos, MD PhD · Universitair Ziekenhuis Brussel

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01732094 on ClinicalTrials.gov